{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:06:22Z","timestamp":1784901982633,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300788"],"award-info":[{"award-number":["32300788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MC119"],"award-info":[{"award-number":["ZR2024MC119"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH201"],"award-info":[{"award-number":["ZR2022QH201"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH173"],"award-info":[{"award-number":["ZR2023QH173"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Macao Young Scholars Program","award":["AM2025028"],"award-info":[{"award-number":["AM2025028"]}]},{"name":"Innovation and Entrepreneurship Training Program for College Students","award":["X2025110650712"],"award-info":[{"award-number":["X2025110650712"]}]},{"name":"Innovation and Entrepreneurship Training Program for College Students","award":["X2025110650770"],"award-info":[{"award-number":["X2025110650770"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08684-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:04:11Z","timestamp":1784822651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinyan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"8684_CR1","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1073\/pnas.80.19.6126","volume":"80","author":"LA Sternberger","year":"1983","unstructured":"Sternberger LA, Sternberger NH. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci USA. 1983;80:6126\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8684_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1084\/jem.174.3.613","volume":"174","author":"SE Stark","year":"1991","unstructured":"Stark SE, Cation AJ. Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions. J Exp Med. 1991;174:613\u201324.","journal-title":"J Exp Med"},{"key":"8684_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","volume":"24","author":"S Paul","year":"2024","unstructured":"Paul S, et al. Cancer therapy with antibodies. Nat Rev Cancer. 2024;24:399\u2013426.","journal-title":"Nat Rev Cancer"},{"key":"8684_CR4","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.","journal-title":"Front Immunol"},{"key":"8684_CR5","doi-asserted-by":"publisher","first-page":"1566869","DOI":"10.3389\/fimmu.2025.1566869","volume":"16","author":"RR Lovewell","year":"2025","unstructured":"Lovewell RR, Langermann S, Flies DB. Immune inhibitory receptor agonist therapeutics. Front Immunol. 2025;16:1566869.","journal-title":"Front Immunol"},{"key":"8684_CR6","doi-asserted-by":"crossref","unstructured":"Deng W, et al. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy. J Nanobiotechnol. 2024;22:97.","DOI":"10.1186\/s12951-024-02297-8"},{"key":"8684_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-immunol-082423-040557","volume":"43","author":"TH Watts","year":"2025","unstructured":"Watts TH, Yeung KKM, Yu T, Lee S, Eshraghisamani R. TNF\/TNFR Superfamily Members in Costimulation of T Cell Responses-Revisited. Annu Rev Immunol. 2025;43:113\u201342.","journal-title":"Annu Rev Immunol"},{"key":"8684_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"LK Ward-Kavanagh","year":"2016","unstructured":"Ward-Kavanagh LK, Lin WW, \u0160ed\u00fd JR, Ware CF. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity. 2016;44:1005\u201319.","journal-title":"Immunity"},{"key":"8684_CR9","doi-asserted-by":"crossref","unstructured":"Jeong S, Park SH. Co-stimulatory receptors in cancers and their implications for cancer immunotherapy. Immune Netw. 2020;20:e3.","DOI":"10.4110\/in.2020.20.e3"},{"key":"8684_CR10","doi-asserted-by":"crossref","unstructured":"Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers 2021;13.","DOI":"10.3390\/cancers13061302"},{"key":"8684_CR11","doi-asserted-by":"crossref","unstructured":"Blanchard L, Mijacika A, Osorio JC. Targeting myeloid cells for cancer immunotherapy. Cancer Immunol Res null. 2025.","DOI":"10.1158\/2326-6066.c.8126019"},{"key":"8684_CR12","doi-asserted-by":"publisher","first-page":"940674","DOI":"10.3389\/fimmu.2022.940674","volume":"13","author":"R Salomon","year":"2022","unstructured":"Salomon R, Dahan R. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy. Front Immunol. 2022;13:940674.","journal-title":"Front Immunol"},{"key":"8684_CR13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1158\/2326-6066.CIR-18-0805","volume":"7","author":"S Ye","year":"2019","unstructured":"Ye S, et al. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity. Cancer Immunol Res. 2019;7:1864\u201375.","journal-title":"Cancer Immunol Res"},{"key":"8684_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","volume":"75","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Richmond A, Yan C. Harnessing the potential of CD40 agonism in cancer therapy. Cytokine Growth Factor Rev. 2024;75:40\u201356.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8684_CR15","doi-asserted-by":"crossref","unstructured":"Luke JJ, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2020-002015"},{"key":"8684_CR16","doi-asserted-by":"crossref","unstructured":"Melero I, et al. 617\u2005A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors. in Regular and Young Investigator Award Abstracts. 2023:A703-A703.","DOI":"10.1136\/jitc-2023-SITC2023.0617"},{"key":"8684_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/cpt.3677","volume":"118","author":"G Bajaj","year":"2025","unstructured":"Bajaj G, et al. Dose Selection for DuoBody\u00ae-CD40x4-1BB (GEN1042\/BNT312) Using a mPBPK\/RO Model Leveraging Preclinical and Clinical Data. Clin Pharmacol Ther. 2025;118:418\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"8684_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/1078-0432.CCR-24-1552","volume":"31","author":"S Piha-Paul","year":"2025","unstructured":"Piha-Paul S, et al. A First-in-Human Study of Cinrebafusp Alfa, a HER2\/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clin Cancer Res. 2025;31:288\u201398.","journal-title":"Clin Cancer Res"},{"key":"8684_CR19","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1200\/JCO.2024.42.16_suppl.2520","volume":"42","author":"C Kyi","year":"2024","unstructured":"Kyi C, et al. Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. J Clin Oncol. 2024;42:2520\u20132520.","journal-title":"J Clin Oncol"},{"key":"8684_CR20","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/blood-2024-205544","volume":"144","author":"MJ Dickinson","year":"2024","unstructured":"Dickinson MJ, et al. BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed\/Refractory Aggressive B-NHL. Blood. 2024;144:3123.","journal-title":"Blood"},{"key":"8684_CR21","doi-asserted-by":"crossref","unstructured":"Johnson M, et al. 735\u2005A phase 1\/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti\u2013PD-1) in patients with advanced solid tumors: initial dose-escalation results in regular and young investigator award abstracts. 2022:A767-A768.","DOI":"10.1136\/jitc-2022-SITC2022.0735"},{"key":"8684_CR22","doi-asserted-by":"crossref","unstructured":"Akce M, et al. A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3). J Clin Oncol. 40:2604\u20132604.","DOI":"10.1200\/JCO.2022.40.16_suppl.2604"},{"key":"8684_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/2767-9764.CRC-25-0638","volume":"6","author":"JJ Harding","year":"2026","unstructured":"Harding JJ, et al. BI 905711, a TRAILR2\/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. Cancer Res Commun. 2026;6:1123\u201335.","journal-title":"Cancer Res Commun"},{"key":"8684_CR24","doi-asserted-by":"crossref","unstructured":"Sum E, et al. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-003264"},{"key":"8684_CR25","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","volume":"27","author":"E Sum","year":"2021","unstructured":"Sum E, et al. Fibroblast Activation Protein \u03b1-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. Clin Cancer Res. 2021;27:4036\u201353.","journal-title":"Clin Cancer Res"},{"key":"8684_CR26","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1038\/s41467-024-53839-5","volume":"15","author":"A Mebrahtu","year":"2024","unstructured":"Mebrahtu A, et al. A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice. Nat Commun. 2024;15:9542.","journal-title":"Nat Commun"},{"key":"8684_CR27","doi-asserted-by":"crossref","unstructured":"Muik A, et al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-004322"},{"key":"8684_CR28","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.tranon.2024.102247","volume":"52","author":"K Du","year":"2025","unstructured":"Du K, Huang H. Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1\/CD40 bispecific antibody for cancer immunotherapy. Transl Oncol. 2025;52:102247.","journal-title":"Transl Oncol"},{"key":"8684_CR29","doi-asserted-by":"crossref","unstructured":"H\u00e4gerbrand K, et al. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-005018"},{"key":"8684_CR30","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-15-0263","volume":"21","author":"A Yonezawa","year":"2015","unstructured":"Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin cancer research: official J Am Association Cancer Res. 2015;21:3113\u201320.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"8684_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ajh.25757","volume":"95","author":"J Timmerman","year":"2020","unstructured":"Timmerman J, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020;95:510\u201320.","journal-title":"Am J Hematol"},{"key":"8684_CR32","doi-asserted-by":"crossref","unstructured":"Segal NH, et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin cancer research: official J Am Association Cancer Res. 2017;23:1929\u201336.","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"8684_CR33","doi-asserted-by":"crossref","unstructured":"Chin SM, et al. Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat Commun. 2018;9:4679.","DOI":"10.1038\/s41467-018-07136-7"},{"key":"8684_CR34","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","volume":"25","author":"MJ Hinner","year":"2019","unstructured":"Hinner MJ, et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB\/HER2 Bispecific Antibody-Anticalin Fusion PRS-343. Clin Cancer Res. 2019;25:5878\u201389.","journal-title":"Clin Cancer Res"},{"key":"8684_CR35","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","volume":"84","author":"H Yuwen","year":"2024","unstructured":"Yuwen H, et al. ATG-101 Is a Tetravalent PD-L1\u00d74-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer Res. 2024;84:1680\u201398.","journal-title":"Cancer Res"},{"key":"8684_CR36","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1007\/s00259-024-06742-6","volume":"51","author":"Z Cao","year":"2024","unstructured":"Cao Z, et al. Radiolabelling and preclinical characterisation of [(89)Zr]Zr-Df-ATG-101 bispecific to PD-L1\/4-1BB. Eur J Nucl Med Mol Imaging. 2024;51:3202\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8684_CR37","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1038\/s41467-021-24767-5","volume":"12","author":"C Geuijen","year":"2021","unstructured":"Geuijen C, et al. A human CD137\u00d7PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12:4445.","journal-title":"Nat Commun"},{"key":"8684_CR38","doi-asserted-by":"crossref","unstructured":"Tacken P, et al. 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1\/PD-L1 signaling while simultaneously activating CD137 signaling on T cells. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2020-SITC2020.0820"},{"key":"8684_CR39","doi-asserted-by":"crossref","unstructured":"Huang PL, et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. J translational Med. 2023;21:346.","DOI":"10.1186\/s12967-023-04410-1"},{"key":"8684_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","volume":"131","author":"SL Buchan","year":"2018","unstructured":"Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131:39\u201348.","journal-title":"Blood"},{"key":"8684_CR41","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-20-0226","volume":"19","author":"Z Kuang","year":"2020","unstructured":"Kuang Z, et al. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment. Mol Cancer Ther. 2020;19:2564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"8684_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/2326-6066.CIR-19-0798","volume":"8","author":"M Gaspar","year":"2020","unstructured":"Gaspar M, et al. CD137\/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. Cancer Immunol Res. 2020;8:781\u201393.","journal-title":"Cancer Immunol Res"},{"key":"8684_CR43","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/2767-9764.CRC-23-0500","volume":"4","author":"CJ Imianowski","year":"2024","unstructured":"Imianowski CJ, et al. IFN\u03b3 Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40\/CD137 Bispecific Agonist Therapy. Cancer Res Commun. 2024;4:2045\u201357.","journal-title":"Cancer Res Commun"},{"key":"8684_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/eji.201040905","volume":"41","author":"A DeBarros","year":"2011","unstructured":"DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, Silva-Santos B. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human \u03b3\u03b4 peripheral blood lymphocytes. Eur J Immunol. 2011;41:195\u2013201.","journal-title":"Eur J Immunol"},{"key":"8684_CR45","doi-asserted-by":"crossref","unstructured":"Vitale LA, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin cancer research: official J Am Association Cancer Res. 2012;18:3812\u201321.","DOI":"10.1158\/1078-0432.CCR-11-3308"},{"key":"8684_CR46","doi-asserted-by":"crossref","unstructured":"He LZ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. Journal of immunology (Baltimore, Md.: 1950). 2013;191:4174\u20134183.","DOI":"10.4049\/jimmunol.1300409"},{"key":"8684_CR47","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","volume":"24","author":"SL Buchan","year":"2018","unstructured":"Buchan SL, et al. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8\u2009+\u2009T-Cell-Driven Antitumor Immunity. Clin cancer research: official J Am Association Cancer Res. 2018;24:2383\u201394.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"8684_CR48","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-020-02610-y","volume":"69","author":"LA Vitale","year":"2020","unstructured":"Vitale LA, et al. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020;69:2125\u201337.","journal-title":"Cancer Immunol Immunother"},{"key":"8684_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02786473","volume":"19","author":"JM Slavik","year":"1999","unstructured":"Slavik JM, Hutchcroft JE, Bierer BE. CD28\/CTLA-4 and CD80\/CD86 families: signaling and function. Immunol Res. 1999;19:1\u201324.","journal-title":"Immunol Res"},{"key":"8684_CR50","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2023023381","volume":"143","author":"J Sam","year":"2024","unstructured":"Sam J, et al. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. Blood. 2024;143:2152\u201365.","journal-title":"Blood"},{"key":"8684_CR51","doi-asserted-by":"publisher","first-page":"e71467","DOI":"10.1002\/cam4.71467","volume":"15","author":"M Nikanjam","year":"2026","unstructured":"Nikanjam M, et al. Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System. Cancer Med. 2026;15:e71467.","journal-title":"Cancer Med"},{"key":"8684_CR52","doi-asserted-by":"crossref","unstructured":"Sainson RC, et al. Abstract LB-153: KY1055, a novel ICOS-PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. Cancer Res. 2018;78:LB-153-LB-153.","DOI":"10.1158\/1538-7445.AM2018-LB-153"},{"key":"8684_CR53","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","volume":"281","author":"A Ashkenazi","year":"1998","unstructured":"Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305\u20138.","journal-title":"Science"},{"key":"8684_CR54","doi-asserted-by":"crossref","unstructured":"Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies (Basel). 2017;6.","DOI":"10.3390\/antib6040016"},{"key":"8684_CR55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jid.2015.12.002","volume":"136","author":"E Szegezdi","year":"2016","unstructured":"Szegezdi E, Leverkus M. Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma. J Invest Dermatol. 2016;136:362\u20134.","journal-title":"J Invest Dermatol"},{"key":"8684_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","volume":"20","author":"JM Garc\u00eda-Mart\u00ednez","year":"2021","unstructured":"Garc\u00eda-Mart\u00ednez JM, et al. Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021;20:96\u2013108.","journal-title":"Mol Cancer Ther"},{"key":"8684_CR57","doi-asserted-by":"crossref","unstructured":"Jung P, et al. A TRAILR2\/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. mAbs 2024;16:2438173.","DOI":"10.1080\/19420862.2024.2438173"},{"key":"8684_CR58","doi-asserted-by":"crossref","unstructured":"Baruch A, et al. Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans. Proc Natl Acad Sci USA. 2020;117:28992\u20139000.","DOI":"10.1073\/pnas.2012073117"},{"key":"8684_CR59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","volume":"26","author":"T Lan","year":"2017","unstructured":"Lan T, et al. FGF19, FGF21, and an FGFR1\/\u03b2-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. Cell Metabol. 2017;26:709\u2013e718703.","journal-title":"Cell Metabol"},{"key":"8684_CR60","doi-asserted-by":"publisher","first-page":"1150222","DOI":"10.3389\/fendo.2023.1150222","volume":"14","author":"AS Aaldijk","year":"2023","unstructured":"Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol. 2023;14:1150222.","journal-title":"Front Endocrinol"},{"key":"8684_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.32742","volume":"78","author":"C Wong","year":"2023","unstructured":"Wong C, et al. Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology. 2023;78:847\u201362.","journal-title":"Hepatology"},{"key":"8684_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","volume":"31","author":"KK Radtke","year":"2025","unstructured":"Radtke KK, et al. Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clin cancer research: official J Am Association Cancer Res. 2025;31:245\u201357.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"8684_CR63","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/14712598.2024.2426636","volume":"24","author":"S Mortaheb","year":"2024","unstructured":"Mortaheb S, Pezeshki PS, Rezaei N. Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy. Expert Opin Biol Ther. 2024;24:1335\u201351.","journal-title":"Expert Opin Biol Ther"},{"key":"8684_CR64","doi-asserted-by":"crossref","unstructured":"Herrera M, et al. Bispecific antibodies: advancing precision oncology. Trends cancer 2024;10:893\u2013919.","DOI":"10.1016\/j.trecan.2024.07.002"},{"key":"8684_CR65","doi-asserted-by":"crossref","unstructured":"Murer P, et al. ANV600 is a novel PD-1 targeted IL-2R\u03b2\u03b3 agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy. J Immunother Cancer. 2025;13.","DOI":"10.1136\/jitc-2025-011905"},{"key":"8684_CR66","doi-asserted-by":"crossref","unstructured":"Sun Y, et al. Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharm Sinica B. 2023;13:3583\u201397.","DOI":"10.1016\/j.apsb.2023.05.023"},{"key":"8684_CR67","doi-asserted-by":"publisher","first-page":"2622746","DOI":"10.1080\/19420862.2026.2622746","volume":"18","author":"G You","year":"2026","unstructured":"You G, et al. Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety. MAbs. 2026;18:2622746.","journal-title":"MAbs"},{"key":"8684_CR68","doi-asserted-by":"publisher","first-page":"1208788","DOI":"10.3389\/fimmu.2023.1208788","volume":"14","author":"G Liu","year":"2023","unstructured":"Liu G, Luo P. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. Front Immunol. 2023;14:1208788.","journal-title":"Front Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08684-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:27:34Z","timestamp":1784899654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08684-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8684"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08684-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This is a review article and no original studies with human participants or animals were performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a review article and no individual patient data or identifiable personal information is included.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"958"}}